GLYXAMBI
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
- Product
- In this atlas
Overview
Technical summary
Drugs@FDA application NDA206073. Original approval 2015-01-30. Efficacy supplement approvals 2016-12-23, 2019-07-03, 2020-03-30. 2 products listed.
Trials at a glance
No registry trial in this atlas names this product.
- Regulatory decisions
- 4
Product details
- Type
- Medicine
- Model or formulation
- Dosage forms in the registry record: TABLET
- Version
- Not stated in the openFDA record
Intended-use sources
No intended-use source is recorded.
The registry's words
Labels as the registry gives them, not rewritten.
- Application
- NDA206073
- Brand name
- GLYXAMBI
- Applicant
- BOEHRINGER INGELHEIM
- Active ingredient
- EMPAGLIFLOZIN
- Active ingredient
- LINAGLIPTIN
- Dosage form
- TABLET
- Route
- ORAL
Claims and evidence
Context FDA record read by the openFDA feed
- Recipient
- Recipient not specified
- Population
- Not stated in the openFDA record
- Care setting
- Not stated in the openFDA record
- Geography
- United States (a decision by the US Food and Drug Administration)
- Life stage
- Not stated in the openFDA record
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
FDA records an approval of NDA206073 on 2015-01-30.
Applies to Recipient not specified FDA record read by the openFDA feed
- Certainty method
- Not assessed
- Limitations
- Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked
- Not recorded
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[10].submission_status_date
- How it applies
- The decision date as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- application_number
- How it applies
- The registry number of the record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[10].submission_status
- How it applies
- The decision status as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
FDA records an approval of efficacy supplement 7 to NDA206073 on 2016-12-23.
Applies to Recipient not specified FDA record read by the openFDA feed
- Certainty method
- Not assessed
- Limitations
- Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked
- Not recorded
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[8].submission_status_date
- How it applies
- The decision date as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- application_number
- How it applies
- The registry number of the record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[8].submission_status
- How it applies
- The decision status as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
FDA records an approval of efficacy supplement 17 to NDA206073 on 2019-07-03.
Applies to Recipient not specified FDA record read by the openFDA feed
- Certainty method
- Not assessed
- Limitations
- Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked
- Not recorded
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[3].submission_status_date
- How it applies
- The decision date as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- application_number
- How it applies
- The registry number of the record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[3].submission_status
- How it applies
- The decision status as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
FDA records an approval of efficacy supplement 21 to NDA206073 on 2020-03-30.
Applies to Recipient not specified FDA record read by the openFDA feed
- Certainty method
- Not assessed
- Limitations
- Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked
- Not recorded
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[7].submission_status_date
- How it applies
- The decision date as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- application_number
- How it applies
- The registry number of the record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA206073 (openFDA record)
- Locator
- submissions[7].submission_status
- How it applies
- The decision status as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4cae4881d061c351da8dbb0ad254b8825d6ea187b42e6fd8bc5925f52e7d9dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
FDA label
Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for this product: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.
- Application
- NDA206073
- Labeler
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Label version
- Version 23, effective
- Label set id
ddbab689-f76c-488c-9613-4168d41dd730- Boxed warning
- No boxed warning
- Sections the label has
- Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this product, oldest first. Each links to its full record.
Authorization
Regulatory decision: GLYXAMBI
- Not stated in the openFDA record
- Not stated in the openFDA record
- United States (a decision by the US Food and Drug Administration)
- Not stated in the openFDA record
- Gestational age Not reported
- Postnatal age Not reported
- Authority
- U.S. Food and Drug Administration
- Decision
- Approval,
- Pathway
- NDA
- Submission
NDA206073- Jurisdictions
- United States
- Product version
- Original application
- Indication
- Not stated in the openFDA record
- Basis
- FDA records an approval of NDA206073 on 2015-01-30.
Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
Regulatory decision: GLYXAMBI
- Not stated in the openFDA record
- Not stated in the openFDA record
- United States (a decision by the US Food and Drug Administration)
- Not stated in the openFDA record
- Gestational age Not reported
- Postnatal age Not reported
- Authority
- U.S. Food and Drug Administration
- Decision
- Supplemental approval,
- Pathway
- NDA
- Submission
NDA206073- Jurisdictions
- United States
- Product version
- Efficacy supplement 7
- Indication
- Not stated in the openFDA record
- Basis
- FDA records an approval of efficacy supplement 7 to NDA206073 on 2016-12-23.
Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
Regulatory decision: GLYXAMBI
- Not stated in the openFDA record
- Not stated in the openFDA record
- United States (a decision by the US Food and Drug Administration)
- Not stated in the openFDA record
- Gestational age Not reported
- Postnatal age Not reported
- Authority
- U.S. Food and Drug Administration
- Decision
- Supplemental approval,
- Pathway
- NDA
- Submission
NDA206073- Jurisdictions
- United States
- Product version
- Efficacy supplement 17
- Indication
- Not stated in the openFDA record
- Basis
- FDA records an approval of efficacy supplement 17 to NDA206073 on 2019-07-03.
Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
Regulatory decision: GLYXAMBI
- Not stated in the openFDA record
- Not stated in the openFDA record
- United States (a decision by the US Food and Drug Administration)
- Not stated in the openFDA record
- Gestational age Not reported
- Postnatal age Not reported
- Authority
- U.S. Food and Drug Administration
- Decision
- Supplemental approval,
- Pathway
- NDA
- Submission
NDA206073- Jurisdictions
- United States
- Product version
- Efficacy supplement 21
- Indication
- Not stated in the openFDA record
- Basis
- FDA records an approval of efficacy supplement 21 to NDA206073 on 2020-03-30.
Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
Record details
- Record id
cardio:fdaprod-nda206073- Content hash
eb4c74477bf8f01ecbe64867fbe4f4cfede56d9aa17756d3d306fd6a5f031495